RxDoctor Payments Data

David Bowlin, MD

Pediatrics · Morgantown, WVNPI 1366412926

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 59.0% of the total. Reporting peaked in 2023 at $226 and has fallen 72.7% since, to $62 in 2024.

$497in general payments, 2019–2025

Across 27 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$293
  • Novo Nordisk$147
  • Novartis$16
  • E.r. Squibb & Sons, L.L.C.$15
  • Johnson & Johnson$14
  • Pfizer$12

What the payments were for

  • Food & beverage$497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)16$293
Novo Nordisk7$147
Novartis1$16
E.r. Squibb & Sons, L.L.C.1$15
Johnson & Johnson1$14
Pfizer1$12

How this compares

$497 in reported general payments places this provider in the 75th percentile of 207 pediatrics providers in West Virginia.

See all pediatrics providers in West Virginia

Medicare billing

Part B allowed, 2024
$86,680
Medicare patients
192
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$244,833
OzempicSemaglutide128$180,260
JanuviaSitagliptin Phosphate43$56,892
EntrestoSacubitril/Valsartan25$38,606
XareltoRivaroxaban29$25,897
JardianceEmpagliflozin20$24,644
MyrbetriqMirabegron21$15,609
Breo ElliptaFluticasone/Vilanterol14$14,657
MultaqDronedarone Hcl11$8,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,410
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$7,468
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,595
Tresiba Flextouch U-100Insulin Degludec11$4,535
SymbicortBudesonide/Formoterol Fumarate13$4,511
Risedronate Sodium48$3,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$244,833197 claims
Novo NordiskOzempic$147$180,260128 claims
NovartisEntresto$16$38,60625 claims
Johnson & JohnsonXarelto$14$25,89729 claims
AbbVieSynthroid$293$1,54830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 pediatrics providers in West Virginia.

Other pediatrics in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →